Budoprutug is under clinical development by Climb Bio and currently in Phase II for Membranous Glomerulonephritis. According to GlobalData, Phase II drugs for Membranous Glomerulonephritis does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Budoprutug LoA Report. Buy the report here.

Related Company Profiles

View all

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Budoprutug overview

Budoprutug (VB-119, DI-B4, TNT-119) is under development for the treatment of primary membranous nephropathy, systemic lupus erythematosus and immune thrombocytopenia. It is administered through intravenous route. The drug candidate is a humanized, immunoglobin (Ig) G1 monoclonal antibody which acts by targeting CD19.
The drug candidate was also under development for the treatment of lupus nephritis, relapsed and refractory indolent B-cell non Hodgkin lymphoma, Waldenstrom macroglobulinemia, chronic lymphocytic leukemia, primary focal segmental glomerulosclerosis and inflammation.

Climb Bio overview

Climb Bio is a clinical-stage biotechnology company focus on developing therapeutics for patients with immune-mediated diseases. The company is headquartered in Wilmington, Delaware, the US.

For a complete picture of Budoprutug’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.